Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
Price : $35 *
At a glance
- Drugs Cinacalcet (Primary) ; Paricalcitol (Primary) ; Calcium; Calcium acetate; Calcium acetate/magnesium carbonate; Lanthanum carbonate; Sevelamer; Vitamin D
- Indications Hyperparathyroidism
- Focus Therapeutic Use
- Acronyms OPTIMAL
- 14 Sep 2015 Planned End Date changed from 1 Oct 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
- 14 Sep 2015 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 14 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.